Abstract
We determined the kinetics of anti-SARS-CoV-2 antibody response in fifteen hospitalized COVID-19 patients. Patients were divided into mild/moderate (mild, n = 1; moderate, n = 4) or severe (n = 10) and virus-specific anti-Nucleocapsid IgM, anti-Spike IgG and anti-Spike IgA were measured in serial serum samples collected 0 to 15 days after hospital admission. Surrogate neutralization assays were performed by testing inhibition of ACE-2 binding to Spike. In 3 patients (2 severe and 1 moderate case), serum antibodies and T-cell memory were monitored 6 months after baseline. Although IgM response tended to appear first, patients affected by less severe disease were more prone to an early IgG/IgA response. Neutralization of Spike binding to ACE2 correlated with anti-Spike IgG and IgA. IgG and IgA antibody response persisted at the 6 months follow-up. A recall T-cell response to the Spike antigen was observed in 2 out of 3 patients, not related to disease severity.
Keywords: COVID-19; Disease Severity; SARS-CoV-2; Serology; T-cell immunity.
【저자키워드】 COVID-19, SARS-CoV-2, serology, disease severity, T-cell immunity, 【초록키워드】 IgG, IgM, ACE2, spike, serology, neutralization, disease severity, Antibody Response, T-cell Response, memory, Antigen, ACE-2, Kinetics, anti-SARS-CoV-2 antibody, Neutralization assay, anti-Spike IgG, IgA, Patient, Mild, Hospital admission, Follow-up, serum antibody, recall, T-cell, moderate, patients, binding, T-cell immunity, severe disease, hospitalized COVID-19 patients, serum antibodies, IgM response, surrogate, serum sample, spike IgA, performed, affected, collected, less, correlated, were measured, the Spike, baseline, 【제목키워드】 IgG, hospitalized COVID-19 patient, severe disease, IgA response, less,